Contribution of Sex Differences to Development of Cardiovascular Disease in Metabolic-Associated Steatotic Liver Disease (MASLD)
International Journal of Translational Medicine · 09.12.2024 · 4 (4) · 782-809
DOI: 10.3390/ijtm4040052 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Translational Medicine, online erschienen am 09.12.2024. Verfasst von Lucy C Taylor und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology & Biophysics, Cardiovascular-Renal Research Center, University of Mississippi Medical Center, 2500 North State Street, Jacks…. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 259 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIDDK NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Sex differences are a complex and crucial variable in developing and progressing metabolic and cardiovascular disease pathophysiology and clinical outcomes. The female sex, compared to the male sex, is protected from metabolic disturbances and their resulting cardiovascular events. However, the peculiar life phases associated with females, such as puberty, pregnancy, and premenopausal and menopausal stages, are all associated with different risks for the development of cardiovascular disease (CVD). Metabolic dysfunction-associated steatotic liver disease (MASLD), a condition of hepatic steatosis, and at least one feature of metabolic syndrome is associated with an increased risk of cardiovascular events. The risk of MASLD and its progression to the development of CVD differs between men and women. Differences in several factors, including formyl peptide receptor (FPR) 2, adipose tissue distribution, liver pyruvate kinase (LPK), and ketone body production, may underlie the sex differences in the risk of development of MASLD-induced CVD. Understanding the specific risk factors involved in the development and progression of MASLD between the sexes is crucial. This knowledge will provide important insights into the mechanisms responsible for its cardiovascular complications and can potentially lead to therapeutics targeted explicitly for each sex, offering new hope in the fight against MASLD-induced CVD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physiology & Biophysics, Cardiovascular-Renal Research Center, University of Mississippi Medical Center, 2500 North State Street, Jackson, Mississippi 39216.
Förderung
- NIGMS NIH HHS
- NIDDK NIH HHS
- NHLBI NIH HHS
- National Institutes of Health
- National Institute of General Medical Sciences
- American Heart Association Postdoctoral Award
Zitieren
APA
Taylor, L. C., Arthur, G., de Carvalho Cruz, M., Stec, D. E., & Badmus, O. O. (2024). Contribution of Sex Differences to Development of Cardiovascular Disease in Metabolic-Associated Steatotic Liver Disease (MASLD). International Journal of Translational Medicine, 4(4), 782-809. https://doi.org/10.3390/ijtm4040052
Vancouver
Taylor LC, Arthur G, de Carvalho Cruz M, Stec DE, Badmus OO. Contribution of Sex Differences to Development of Cardiovascular Disease in Metabolic-Associated Steatotic Liver Disease (MASLD). International Journal of Translational Medicine. 2024;4(4):782-809. doi:10.3390/ijtm4040052
BibTeX
@article{Taylor2024,
author = {Taylor, Lucy C and Arthur, Gertrude and de Carvalho Cruz, Marcella and Stec, David E and Badmus, Olufunto O},
title = {Contribution of Sex Differences to Development of Cardiovascular Disease in Metabolic-Associated Steatotic Liver Disease (MASLD)},
journal = {International Journal of Translational Medicine},
year = {2024},
volume = {4},
number = {4},
pages = {782--809},
doi = {10.3390/ijtm4040052}
}
EUVIMED